In the final feature explaining why Senda Biosciences is a Company to Watch, Big4Bio editor Marie Daghlian spoke with Senda Chief Scientific Officer Luke O’Neill about why he joined the company, why he is excited to be a member of Senda’s team, and what we might expect from them in the near future. Companies to […]
senda
Podcast: Pioneering Fully Programmable Medicines
/ big4bio
In the third of four features on Senda Biosciences, we spoke to Senda CEO Guillaume Pfefer and Senda Chief Platform Officer Stuart Milstein, about its platform technology, how it is building an atlas of natural nanoparticles, and how its work is leading to a pipeline of programmable medicines. Companies to Watch – Senda Biosciences The Big4Bio […]
Medicines with Unlimited Possibility
/ big4bio
The second of four features on Senda Biosciences, based on Big4Bio’s interview with CEO Guillaume Pfefer and Chief Platform Officer Stuart Milstein, focuses on the company’s technology platform – designed to harness nature’s codes to program molecules within and to the cell – and its potential to treat a broad range of diseases. Companies to […]
The Big4Bio Company to Watch Program
April 2023: Senda Biosciences
April 2023: Senda Biosciences
/ big4bio
THE COMPANY/THE MISSION Programming Medicine to Send the Right Information to the Right Cell Senda Biosciences is on a mission to harness powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines. THE TECHNOLOGY, PART 1 Medicines with Unlimited Possibility Discussing the company’s technology […]
Programming Medicine to Send the Right Information to the Right Cell
/ big4bio
In the first of four features on Senda Biosciences, Big4Bio spoke with CEO Guillaume Pfefer and Chief Platform Officer Stuart Milstein about how and why the company was founded, and how molecular connections among different kingdoms of life that have co-evolved over millennia may hold the key to addressing the challenges of delivering nucleic acid […]